Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.

Benha University20 enrolled

Overview

The primary objective of this study was to evaluate the change in serum interferon gamma and Interleukin-15 levels before and after use of oral drug baricitinib therapy. Venous blood samples (5 mL) were collected from each participant at baseline and at six months.

Changes at baseline and immediately after 6 mmonths will be analyzed, primary outcome is the changes in serum levels over 6 months, while secondary outcome is changes in the Severity of Alopecia Tool (SALT score) over 6 months.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Alopecia Areata

Interventions

Baricitinib 4 MG Oral TabletDRUG

All cases will use oral Baricitinab 4mg daily dose for six months.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults diagnosed clinically with Alopecia Areata. * Severity of alopecia tool (SALT) score greater than 50. * Only patients with disease duration exceeding six months but less than eight years will be included. Exclusion Criteria: * Patients were excluded if they were pregnant or lactating, and had chronic hepatic or renal disease. * Cases diagnosed with malignancy, scalp infections, or other types of alopecia will also excluded from the current study. * Recent use of systemic treatment within the last 3 months or topical treatment within the last 4 weeks also will be excluded.

Locations (1)

Faculty of medicine, Benha University (Dermatology department)

Banhā, Egypt

Outcomes

Primary Outcomes

Serum level of Interleukin-15.

Measuring the serum level of Interleukin-15 at baseline and immediately after 6 months of Baricitinab 4mg oral therapy. Measurement is done using Enzyme-Linked Immunosorbent Assay (ELISA) laboratory technique.

Time frame: At baseline and immediately after 6 months of follow up.

Serum level of Interferon Gamma.

Measuring the serum level of Interferon Gamma at baseline and immediately after 6 months of Baricitinab 4mg oral therapy. Measurement is done using Enzyme-Linked Immunosorbent Assay (ELISA) laboratory technique.

Time frame: Baseline and immediately after 6 months of Baricitinab 4mg oral therapy.

Secondary Outcomes

Changes in the Severity of Alopecia Tool (SALT) score

Severity of Alopecia Tool (SALT) score is a standardized measurement used by dermatologists to quantify scalp hair loss, ranging from 0 (no hair loss) to 100 (complete baldness). It is calculated by adding the weighted percentages of hair loss from four scalp quadrants: vertex (40%), posterior (24%), right profile (18%), and left profile (18%).

Time frame: At Baseline and immediately after 6 months of oral Baricitinab 4mg oral therapy.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.